SCHEMBL6473402

SCHEMBL6473402

CCCCCCCC(=O)N(C)Cc1cccc(Br)c1.c1ccc2c(c1)CO2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
BCHE P06276 3/20 0.41
ACHE P22303 3/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
MAPT P10636 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
AOC3 Q16853 1/20 0.37
PTGES O14684 1/20 0.36
PYCR1 P32322 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67832 0.87 RIPK1 (0.60) RIPK1BCHEACHENPC1RAB9A
SCHEMBL6473350 0.84 RIPK1 (0.48) RIPK1BCHEACHENPC1RAB9A
SCHEMBL27740940 0.76 RIPK1 (0.54) RIPK1KMT2ATMEM97SIGMAR1CYP1A2
SCHEMBL5361863 0.75 AOC3 (0.53) RIPK1AOC3
SCHEMBL14946877 0.74 NPC1 (0.72) RIPK1BCHEACHENPC1RAB9A
SCHEMBL7761239 0.74 NPC1 (0.72) RIPK1BCHEACHENPC1RAB9A
SCHEMBL8017184 0.74 NPC1 (0.72) RIPK1BCHEACHENPC1RAB9A
SCHEMBL29565583 0.72 RIPK1 (0.65) RIPK1NPC1RAB9AKMT2AAOC3
Hexanoate SCHEMBL4559406 0.71 AKR1B1 (0.50) KMT2AMAPT
SCHEMBL13639173 0.70 NPC1 (0.53) BCHEACHENPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD RIPK1 2311/4885BCHE 1768/4885ACHE 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.